SAB Biotherapeutics, Inc. (SABS) Stock Price & Analysis
SAB Biotherapeutics, Inc. (SABS) — MoonshotScore 47/100 (Fair band), calculated Nov 22, 2026. Price $2.81 (-3.44%), as of the Nov 20, 2026 trading session; market cap $253M.
Educational signal · not a buy or sell recommendation · How to read this
SAB Biotherapeutics, Inc. · SABS · NASDAQ
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human antibody immunotherapies. Their DiversitAb platform utilizes genetically engineered bovine herds to produce fully human polyclonal antibodies for infectious diseases, autoimmune disorders, and cancer.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · SAB Biotherapeutics (SABS)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Stalling growth and a full valuation, though quality is only middling. Business Quality: Average; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 3 of the last 8 reports
- Altman Z 4.40 · Piotroski F 1
- ROE -40.0% · ROA -34.2% · current ratio 7.28 · earnings yield -29.2% · free-cash-flow yield -27.8%
Holding back: soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 49 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair | |
| 47 | Fair |
The score was 47 in the stored Nov 21, 2026 snapshot and remains 47 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Business Quality +1 and Valuation -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $2.81 | |
| Change on the day | -3.44% | |
| Market capitalisation | $253M | — |
| Price / earnings (trailing) | 0.89 | |
| Shares traded on the day | 874.6K |
Price & events
Other perspectives
Council score for SAB Biotherapeutics (SABS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 30, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 30, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is SAB Biotherapeutics (SABS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. SAB Biotherapeutics, Inc. (SABS) is listed on NASDAQ. It employs 86 people. The market values it at $253M.
What do the latest results show for SAB Biotherapeutics (SABS)?
Short answer · as of
Against analyst estimates the company has EPS beat 3 of the last 8 reports.
What are the financial strengths and risks for SAB Biotherapeutics (SABS)?
Short answer · as of
What is holding it back is soft growth. The distress and quality screens read Altman Z 4.40 · Piotroski F 1. Trailing ratios: ROE -40.0% · ROA -34.2% · current ratio 7.28 · earnings yield -29.2% · free-cash-flow yield -27.8%.
Data-derived red flags
- Negative return on equity (-40.0%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at SAB Biotherapeutics (SABS)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $333,333 · EPS -1.08 · 5 analysts. The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for SABS.
Checked against the records this page reads, on the dates shown above.
How does SAB Biotherapeutics compare with its peers?
Short answer
SAB Biotherapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.09 Nov 20, 2026 | $462M | 92 5-pillar Nov 22, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 22, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 22, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 87 5-pillar Nov 22, 2026 | |
| $10.92 Nov 20, 2026 | $99.3M | 82 5-pillar Nov 22, 2026 | |
| $15.47 Nov 20, 2026 | $83.3M | 82 5-pillar Nov 22, 2026 | |
| $3.57 Nov 20, 2026 | $155M | 72 5-pillar Nov 22, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 70 5-pillar Nov 22, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 22, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 22, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 64 5-pillar Nov 22, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 22, 2026 | |
| SAB Biotherapeutics (SABS) — this page | $2.81 | $253M | 47 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $11.00 – $13.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $12.00
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $12.00
- Revenue estimate
- $333,333
- EPS estimate
- $-1.08
Historical target record · Captured · Capture expired; not a current watchpoint.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SABS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SABS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about SAB Biotherapeutics (SABS)?
SAB Biotherapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the SABS research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for SABS?
SABS carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human antibody immunotherapies.
Is SABS a good stock to buy?
Stock Expert AI does not rate SABS buy, sell or hold. SAB Biotherapeutics, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SABS stock price today?
The last price recorded for SAB Biotherapeutics, Inc. (SABS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SABS price target?
The last analyst consensus price target we captured for SAB Biotherapeutics, Inc. (SABS), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What are the main risks for SABS?
The main risks for SAB Biotherapeutics, Inc. include the inherent uncertainties of clinical-stage drug development, such as potential trial failures or delays.
What are the key factors to evaluate for SABS?
SAB Biotherapeutics, Inc. (SABS) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. DiversitAb platform offers a unique approach to producing fully human polyclonal antibodies without the need for human donors. Not financial advice.
How frequently does SABS data refresh on this page?
SABS's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SABS's recent stock price performance?
SAB Biotherapeutics, Inc. (SABS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative DiversitAb platform for antibody production. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SABS overvalued or undervalued right now?
The trailing P/E of SAB Biotherapeutics, Inc. (SABS) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 18 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com